Orlando, FL (PRWEB) April 30, 2013
Anolinx, a clinical research and clinical trials recruitment company headquartered in Salt Lake City, Utah, announced today the launch of a new patient recruitment initiative.
Anolinx made the announcement in conjunction with the annual Partnerships in Clinical Trials conference in Orlando, FL.
According to Anolinx CEO, Aaron Kamauu MD MS MPH, the company is now poised to utilize real world “big data” for the purpose of recruiting patients for clinical trials. Dr. Kamauu, said at the press conference, “Our mission is quite simple: Use advanced analytics on current, deep and rich, real world data to identify and recruit clinical trials patients much faster and with greater precision.”
“Over the last two years we have proven the success of this model and are now prepared to launch our capabilities on a large scale. We have the analytics and the data to do this work,” he added.
Anolinx also announced two well-known thought leaders in healthcare as Chairman of the Board of Directors and Chairman of the Board of Advisors. Senator Robert F. Bennett will serve as Chairman of the Board of Directors and Raymond L. Woosley, MD PhD will serve as Chairman of the newly created Board of Scientific Advisors.
Senator Bennett, a former three-term Senator from Utah, is widely known for his healthcare expertise. While in the Senate he served as Chairman of the Appropriations Subcommittee on Agriculture, (the Senate committee with FDA budget oversight). He was also the co-author of the Bennett-Wyden healthcare bill, a health care proposal respected across the political spectrum as a common sense approach to healthcare reform. Senator Bennett also brings deep business experience to Anolinx, having served as CEO of a NYSE traded public company prior to his Senate service.
“I am delighted to be joining Anolinx,” said Senator Bennett. “I spent much of my Senate career on the committee that oversees the FDA budget. The cost and time to market of new medicines always have been major concerns, to drug manufacturers and consumers alike. What we are doing at Anolinx is the first real breakthrough I have seen in efforts to deal with these issues.”
Dr. Woosley is among the giants of medicine and clinical pharmacology in America. He was the Chairman of the Department of Pharmacology and Associate Dean for Clinical Research at Georgetown University Medical Center and Vice-President and Dean of the College of Medicine at the University of Arizona. Founder of the Critical Path Institute (C-Path), Dr. Woosley is widely known and widely published in the field of Clinical Pharmacology and Cardiology.
Dr. Woosley said, “The inefficient way we recruit patients for clinical trials and the time it takes to bring drugs to market is unacceptable and unsustainable. Also, many trials fail because the patients enrolled in trials do not have the optimal characteristics and the expected outcomes. I have spent a good portion of my career thinking about these issues. I believe Anolinx will be a real leader in changing the recruitment paradigm. I’m excited to be a part of this innovative, forward-looking team.”
Anolinx specializes in analyzing electronic health/medical records (EHR/EMR) for a variety of clinical research projects, including pharmacoepidemiology, outcomes research, data-driven site identification, data-driven patient identification and recruitment, and patient registries.
Anolinx analyzes real-world data to identify the correct sites and ideal patients for specific trials. The company’s “heat maps” overlay locations with sites by patient counts so clients can get a snapshot of the viability and the likelihood of success before beginning a trial.
According to Dr. Kamauu, “Our unparalleled access to vast amounts of big and deep data and advanced analytics, allows us to recruit qualified patients faster. The result will be a much shorter time to market for new medicines.”
Anolinx is a data-driven clinical research and clinical trials recruitment company that digs deep into electronic health records to significantly improve recruitment and reduce the cost and time for completion of clinical trials. Our unprecedented access to current real-world healthcare data and our advanced analytics enable us to recruit clinical trial patients faster and with greater precision so that our clients can get new medicines to market sooner.